GSK’s Blenrep Hit By Trial Failure, Raising Questions About Its Future In The Myeloma Market

Phase III Study Misses Endpoint

Nov 07 2022

DREAMM-3's failure does not bode well for further readouts in earlier myeloma therapy, and could even see Blenrep removed from the market. • Source: GSK

GSK’s Blenrep Hit By Trial Failure, Raising Questions About Its Future In The Myeloma Market

Phase III Study Misses Endpoint

More from Clinical Trials

More from R&D